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Objective: Although well characterized in several solid tumors, the effects of
Fas/Fas ligand interactions in malignant pleural mesothelioma cells have not been
defined. The present study was undertaken to examine the functional status of the
Fas/Fas ligand pathway in malignant pleural mesothelioma cells and to determine
the feasibility of targeting this death-signal pathway for molecular intervention in
patients with mesotheliomas.
Methods: Fas expression in primary normal human bronchial epithelial cells and 6
malignant pleural mesothelioma cell lines was quantified by means of flow cytom-
etry. The caspase components of the Fas-mediated apoptotic pathway were evalu-
ated by means of Western blot techniques. Soluble Fas ligand–mediated
cytotoxicity and apoptosis were evaluated by means of MTS and TUNEL assays,
respectively. Cisplatin (3 µg/mL) and lymphokine-activated killer cells were used
to enhance mesothelioma sensitivity to soluble Fas ligand. An H2373 nude mouse
xenograft model of malignant pleural mesothelioma was established to assess the in
vivo effects of soluble Fas ligand.
Results: Four of 6 malignant pleural mesothelioma lines exhibited high levels of Fas
expression, and 2 of 4 were inherently susceptible to soluble Fas ligand–mediated
cytotoxicity (soluble Fas ligand 50% inhibitory concentration, <15 ng/mL). Two
soluble Fas ligand refractory cell lines (H2052 and H513) exhibited high levels of
Fas receptor. Pretreatment with cisplatin resulted in a reduction of 50% inhibitory
concentration from infinity to 4.17 ± 0.14 ng/mL and 10.23 ± 1.58 ng/mL, respec-
tively. Two additional soluble Fas ligand refractory cell lines (H2595 and REN)
expressed low levels of Fas. Exposure of these cells to lymphokine-activated killer
cells or lymphokine-activated killer cell–conditioned medium followed by a 24-
hour treatment with cisplatin resulted in a significant reduction in 50% inhibitory
concentration of soluble Fas ligand and pronounced induction of apoptosis.
Intraperitoneally administered soluble Fas ligand mediated regression of H2373
xenografts.
Conclusion: The Fas/Fas ligand pathway in mesothelioma cells is either intrinsically
intact or can be rendered functional with chemotherapeutic agents or immune effec-
tor cells. These preclinical data support further evaluation of strategies to enhance
Fas-mediated apoptosis in mesotheliomas.
Malignant pleural mesothelioma (MPM) afflicts approximately2500 Americans annually.1 Although still relatively uncom-mon, the incidence of mesothelioma has risen dramaticallyduring the past 2 decades as a result of asbestos exposure.More recently, simian virus 40 has been implicated as acocarcinogen in the pathogenesis of this disease.2 Because
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nearly 100 million Americans were exposed to simian virus
40 during polio vaccination, the number of mesothelioma
cases is expected to increase for the next 20 to 30 years.
Currently, the overall survival of patients with mesothe-
lioma ranges between 3% and 6%, despite aggressive mul-
timodality intervention.1 These data highlight the need for a
more fundamental appreciation of the pathogenesis of
MPM and the rational design of novel therapies targeting
molecular defects in this disease.3
Dysregulation of death-signal pathways, such as the one
mediated by the Fas (Apo-1/CD95) receptor, have been
described in a variety of malignancies.4,5 Fas is a member
of the tumor necrosis factor receptor super family, which is
widely expressed in normal and transformed cells of differ-
ent histologic types.6 On binding with a specific ligand (Fas
ligand [FasL]), Fas receptors form homotrimers that recruit
intracellular adaptor molecules that activate caspase 8,
thereby initiating the cleavage of downstream caspases and
resulting in mitochondrial disruption and apoptosis in sus-
ceptible cells.7-9
Fas/FasL interactions maintain homeostasis in normal
tissues and are believed to contribute to immune surveil-
lance, enhancing perforin/granzyme-mediated target cell
lysis by lymphokine-activated killer (LAK) cells and nat-
ural killer cells, as well as cytolytic T lymphocytes.10-12
Although a significant percentage of malignant cells
express the Fas receptor, not all of them are intrinsically
susceptible to FasL-mediated apoptosis.5 Furthermore,
recent data suggest that expression of FasL expressed on
tumor cells can engage Fas receptor on cytolytic T lympho-
cytes, resulting in the clonal deletion of tumor-reactive
immune effector cells.13,14
Although the Fas/FasL pathway has been extensively
studied in several tumor histologic types, especially
melanomas, limited information is available regarding the
functional status of this pathway in MPMs. In the present
study we sought to examine the role of the Fas/FasL path-
way in mediating apoptosis in a panel of MPM cell lines.
Herein we report that the majority of these lines express
adequate levels of Fas receptor, yet only one third of them
are inherently sensitive to soluble Fas ligand (sFasL). In the
remaining cell lines the Fas/FasL pathway could be ren-
dered functional by exposure to cisplatin (CDDP) alone or
exposure to LAK cells or LAK-conditioned media, fol-
lowed by CDDP. These data suggest that manipulation of
the Fas/FasL pathway may be a novel strategy to induce
apoptosis in MPMs.
Materials and Methods
Cells and Reagents
H28 (sarcomatoid histology), H2373 (sarcomatoid histology),
H2052 (sarcomatoid histology), H513 (epitheliod histology),
H2595 (sarcomatoid histology), and REN (sarcomatoid histology)
MPM cell lines and Jurkat T-cell leukemia lines were available in
tissue-culture banks at the National Institutes of Health and were
maintained in RPMI medium supplemented with glutamine (1
mmol/L), streptomycin (100 mg/mL), penicillin (100 U/mL), and
10% fetal calf serum. Normal human bronchial epithelial (NHBE)
cells and human umbilical vein endothelial cells (Clonetics Corp,
San Diego, Calif) were cultured, as recommended by the vendor.
Recombinant sFasL and enhancer protein were obtained from
Alexis Corporation (San Diego, Calif) and reconstituted according
to the manufacturer’s instructions. Fluorescein isothiocyanate–
conjugated anti-Fas monoclonal antibody and monoclonal anti-
bodies recognizing caspases 3, 8, and 9 were purchased from
PharMingen (San Diego, Calif). 
Western Blot Analysis of Caspases 3, 8, and 9 in
Human Umbilical Vein Endothelial Cells and MPM
Cells
MPM cell lysates were electrophoresed and electroblotted onto a
polyvinylidene difluoride (PVDF) membrane (Bio-Rad
Laboratories, Hercules, Calif). The PVDF membranes were then
Figure 1. Flow cytometric analysis of Fas expression in mesothe-
lioma and control cells. Jurkat cells, which express high levels of
Fas, were used as positive controls for subsequent experiments.
These data are representative of 3 independent experiments that
yielded similar results.
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blocked with a 5% lowfat milk/Tris-buffered saline/Tween solu-
tion and exposed overnight to antibodies recognizing caspase 3, 8,
and 9 (Pharmingen) or β-actin. The PVDF membranes were then
washed and incubated with appropriate horseradish
peroxidase–conjugated secondary antibodies. Protein-antibody
conjugates were detected with ECL techniques (Amersham
Pharmacia Biotech Inc, Piscataway, NJ).
In Vitro FasL-mediated Cytotoxicity
Cells were seeded in flat-bottom, 96-well plates and, after
overnight incubation, were treated with sFasL at concentrations
ranging from 1 to 100 ng/mL for 24 hours. For CDDP-sFasL com-
bination experiments, cells were exposed to CDDP (3 µg/mL) for
24 hours before sFasL treatment. Cell viability was quantitated
with the MTS assay (Cell Titer 96 Aqueous One Solution Cell
Proliferation Assay; Promega Corp, Madison, Wis). Soluble FasL-
mediated cytotoxicity dose-response curves were plotted as the
fraction of viable cells relative to untreated control cells versus
sFasL concentrations. In CDDP/sFasL sequential experiments,
cells treated with CDDP alone served as control cells to correct for
minor growth inhibitory effects of this DNA damaging agent. The
sensitivity of MPM cells to sFasL-mediated cytotoxicity was
determined by estimating sFasL inhibitory concentration of 50%
(IC50) values from their respective dose-response curves. A lower
IC50 value indicated increased susceptibility to the cytotoxic
effects of sFasL. Induction of apoptosis after sFasL treatment,
Figure 2. Upregulation of Fas expression in H2595 (A) and REN (B) MPM cell lines after 24 hours’ exposure to either
LAK cells or cell-free LAK supernatant. Incubation of these lines with fresh basal LAK medium without (control) or
with interferon γ (100 IU/mL) did not alter the basal expression of Fas. These data are representative of 3 independent
experiments that yielded similar results.
TABLE 1. sFasL IC50 values for malignant plural mesothelioma cells and normal human bronchial epithelial cells
Cell line SFasL alone CDDP + sFasL LAK/LAK supernatant LAK supernatant/CDDP
H28 7.53 ± 2.87 8.54 ± 1.62 ND ND
H2373 10.51 ± 1.75 9.28 ± 2.34 ND ND
H2052 ∞ 4.17 ± 0.14 ND ND
H513 ∞ 10.23 ± 1.58 ND ND
H2595 ∞ ∞ ∞ 45.30 ± 3.2
REN ∞ ∞ ∞ 26.80 ± 2.58
NHBE 80 ± 4.40 91.42 ± 9.87 81.63 ± 5.70 87.86 ± 7.89
These data are means ± SD of 3 independent experiments. ND, Not determined.
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with or without prior exposure to CDDP, was evaluated with pro-
tocols and reagents contained in the Apo-BrdU kit (Pharmingen).
Exposure of MPM Cells to LAK Cells or Supernatant
Peripheral blood mononuclear cells from normal volunteers were
cultured in basal LAK medium (RPMI supplemented with 2%
human AB serum, 1000 U/mL interleukin 2, 1 mmol/L glutamine,
100 mg/mL streptomycin, and 100 U/mL penicillin) to generate
LAK cells. LAK-conditioned medium was prepared by centrifug-
ing 3-day-old LAK supernatants at 1500 rpm for 10 minutes to
remove cellular components; conditioned medium was stored at
–80°C for subsequent experiments.
Adherent MPM cells were either coincubated with LAK cells
at an effector/target ratio of 10:1 or exposed to cell-free LAK-con-
ditioned medium for 24 hours. Subsequently, MPM cells were
washed 3 times with RPMI and either analyzed for Fas expression
by means of flow cytometric techniques with a fluorescein isoth-
iocyanate–labeled anti-Fas monoclonal antibody or used in FasL-
mediated cytotoxicity assays.
MPM Human Xenograft in Nude Mice
In 2 independently performed experiments, 5 groups (5
animals/group) of athymic nude mice received intraperitoneal
injection of 106 H2373 MPM cells suspended in 1 mL of Hanks
buffered saline solution (HBSS). At either 1 or 2 weeks after tumor
inoculation, mice in the treatment groups received intraperitoneal
injections of sFasL (100 ng of sFasL dissolved in 1 mL of HBSS)
3 times per week for 3 weeks. Control animals received sham
injections of HBSS only. One week after completion of treatment,
all animals were killed, and intraperitoneal tumor burden was
recorded by means of digital photography. All animals were
treated in accordance with the Animal Welfare Act.
Results
Phenotypic Analysis of Fas and Caspase Expression in
MPM Cells
Four MPM lines (H28, H513, H2052, and H2373)
expressed levels of Fas receptor equal to or exceeding the
level noted in NHBE cells, whereas 2 lines (H2595 and
REN) exhibited Fas expression that was lower than that
seen in normal cells (Figure 1). Treatment with CDDP or
interferon γ, both of which can induce Fas expression in
some tumor cells,15,16 failed to upregulate surface Fas
expression in H2595 and REN cells. On the other hand, 24-
hour exposure to LAK cells or LAK-conditioned medium
profoundly increased Fas expression in these 2 lines (Figure
2). Western blot analysis revealed that all of the MPM lines
expressed abundant levels of caspases 3, 8, and 9 (Figure 3),
which are essential for mediating apoptosis after Fas/FasL
interaction.
In Vitro Functional Analysis of Fas-mediated
Cytotoxicity
Treatment of either H28 or H2373 MPM cells, which
express adequate levels of Fas receptor, with sFasL resulted
in significant cytotoxicity (sFasL IC50 values of 7.53 ± 2.87
and 10.51 ± 1.75 ng/mL, respectively). H28 and H2373
cells were 8 to 10 times more sensitive to sFasL-mediated
cytotoxicity relative to NHBE cells (sFasL IC50, 80 ± 4.40
ng/mL). Interestingly, although expressing adequate levels
of Fas, H513 and H2052 cells were refractory to sFasL-
induced cytotoxicity, as evidenced by sFasL IC50 values
approaching infinity (∞). H2595 and REN cells also were
resistant to sFasL.
Figure 3. Western blot analysis of caspases 3, 8, and 9 in human
umbilical vein endothelial cells (HUVECs) and MPM cells.
Figure 4. Induction of apoptosis in Jurkat lymphoma, H28, and
H2373 mesothelioma cells and NHBE cells after exposure to
sFasL. These sFasL-sensitive tumor cells underwent significant
apoptosis after treatment with 50 ng/mL sFasL. No apoptosis was
detected in NHBE cells under similar conditions. These data are
means ± SD of 3 independent experiments.
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Strategies to Enhance Susceptibility of Resistant MPM
Cells to sFasL-mediated Cytotoxicity
Exposure of Fas-positive H2052 and H513 MPM cells to a
sublethal dose of CDDP (3 µg/mL) resulted in significant
sensitization to the cytotoxic effects of sFasL, as evidenced
by a reduction in sFasL IC50 from ∞ to 4.17 ± 0.14 and
10.23 ± 1.58 ng/mL, respectively; similar treatment of
H2595 and REN cells failed to sensitize them to sFasL.
Twenty-four–hour exposure to LAK cells or LAK-condi-
tioned medium induced Fas expression in H2595 and REN
cells to levels comparable with what was observed in unma-
nipulated NHBE cells; however, these mesothelioma cells
remained resistant to sFasL. Additional experiments
revealed that CDDP (3 µg/mL) administered subsequent to
upregulation of Fas expression markedly sensitized H2595
and REN cells to sFasL-mediated cytotoxicity. Similarly
treated primary normal human epithelial cells were not fur-
ther sensitized to sFasL-mediated cytotoxicity (Table 1).
Induction of Apoptosis as the Mechanism of sFasL-
mediated Cytotoxicity
Significant apoptosis was noted in H28 and H2373 cells 24
hours after exposure to 50 ng/mL sFasL (40.37% ± 6.55%
and 20.14% ± 8.85% vs 3.05% ± 0.78% and 3.80% ±
0.86%, respectively; Figure 4); in contrast, NHBE cells
were quite resistant to this treatment. Soluble FasL-medi-
ated apoptosis in MPM cells was completely inhibited by
the caspase inhibitor zVAD (20 µmol/L) or sFas (100
ng/mL, data not shown). CDDP alone exhibited limited
proapoptotic effects in Fas-positive, sFasL-resistant H2052
and H513 cells. Interestingly, sFasL markedly enhanced
apoptosis in CDDP-treated cells (Figure 5). Apoptosis
induced by sequential CDDP/sFasL treatment was also
blocked by zVAD or sFas, underscoring the essential role of
Fas/FasL interaction in this process.
sFasL Mediates Tumor Regression in H2373 Nude
Mouse Xenografts
Intraperitoneal inoculation of 106 H2373 MPM cells
resulted in extensive carcinomatosis that was consistently
observed within 6 weeks in untreated animals (Figure 6, A).
Intraperitoneal injection of sFasL (100 ng in 1 mL of
HBSS) 3 times per week for 3 weeks commencing 1 week
after tumor inoculation (the time at which there was only
microscopic tumor cell implantation; Figure 6, B) markedly
inhibited the development of intra-abdominal carcinomato-
sis (Figure 6, C). Initiation of sFasL treatment 2 weeks after
tumor cell inoculation (the time at which there were macro-
scopic tumor implants; Figure 6, D) also inhibited tumor
growth (Figure 6, E), albeit to a lesser extent than when
treatment was initiated for microscopic tumor burden.
Discussion
Induction of apoptosis through the Fas/FasL pathway has
been examined in various histologic categories.17-19
However, limited information is available regarding the
Figure 5. Induction of apoptosis in H2052 (A) and H513 (B) MPM cells after exposure to normal medium, sFasL alone
(50 ng/mL for 24 hours), CDDP (3 µg/mL for 24 hours) alone, or CDDP-sFasL. These data are representative of 3 inde-
pendent experiments that yielded similar results.
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functional status of the Fas/FasL pathway in MPMs and the
feasibility of targeting this pathway for the treatment of
patients with this highly lethal disease.
Phenotypic and functional analysis of the Fas-mediated
death-signal pathway in this small but representative panel of
cultured MPM cells revealed 3 distinct subgroups with respect
to Fas expression and FasL-mediated cytotoxicity. The first
group (represented by H28 and H2373 cells) expressed ade-
quate levels of Fas and appeared to be intrinsically sensitive to
sFasL-mediated apoptosis. The second group (including
H2052 and H513) also expressed adequate levels of Fas but
appeared refractory to sFasL; treatment of these 2 cell lines
with a sublethal dose of CDDP for 24 hours significantly
enhanced their susceptibility to sFasL-mediated apoptosis.
The last group (represented by H2595 and REN cells) also
appeared refractory to sFasL. Pretreatment with CDDP or
interferon γ failed to upregulate Fas in these 2 mesothelioma
lines. In contrast, LAK cells or LAK-conditioned medium did
induce Fas expression in H2595 and REN cells, thereby
enabling CDDP-mediated sensitization to sFasL.
Figure 6. In vivo response of H2373 MPM xenograft to locoregional delivery of sFasL: A, tumor burden 6 weeks after
injection of H2373 MPM cells; B, tumor burden 1 week after injection of H2373 MPM cells; C, inhibition of tumor
growth after treatment with sFasL commencing 1 week after tumor implantation; D, tumor burden 2 weeks after
implantation of H2373 MPM cells; E, response to sFasL injections starting 2 weeks after tumor implantation. A simi-
lar magnitude of response was observed in all animals within each group. Representative digital photographs are
shown here.
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The ability of CDDP to enhance responsiveness to sFasL
in tumor cells has been described previously20-22; however,
the mechanisms underlying this phenomenon have not been
defined. CDDP is known to induce reactive oxygen species,
which render cells susceptible to apoptotic signals.23
Conceivably, reactive oxygen species resulting from DNA
damage can prime mesothelioma cells to undergo apoptosis
through Fas pathways. Interestingly, exposure to CDDP did
not affect the intrinsic sensitivity of FasL-responsive
mesothelioma cells.
A more interesting issue emanating from our study is the
upregulation of Fas expression in Fas-negative cells after
exposure to LAK cells or LAK-conditioned medium.
Exposure to cytolytic T lymphocytes induces Fas expres-
sion in murine fibrosarcoma cells by mechanisms that are
currently unclear.24 In the present study induction of Fas in
H2595 and REN cells cannot be attributable to interferon γ
or interleukin 2 because interferon γ alone did not upregu-
late Fas expression, and interleukin 2 was present in LAK
control culture medium, as well as in LAK supernatants.
These findings suggest that LAK-mediated enhancement of
Fas expression in MPM cells is regulated by currently
unidentified cytokines in 3-day-old LAK-conditioned
medium. The fact that CDDP was required to induce sFasL-
mediated apoptosis in H2595 and REN cells after exposure
to LAK cells or LAK-conditioned medium indicates that
restoration of Fas expression to normal levels is necessary
but not always sufficient to induce apoptosis in mesothe-
lioma cells.
It is widely recognized that sFasL can induce apoptosis
in a variety of tumor histologic types.25 However, its thera-
peutic potential is hampered by the fact that normal tissues
possess Fas receptor and therefore are sensitive to Fas-
mediated apoptosis.26 Although not practical for systemic
administration, sFasL could prove efficacious for locore-
gional therapy of mesotheliomas. Our studies demonstrated
that intraperitoneal administration of sFasL significantly
inhibited the growth of MPM xenografts, without obvious
regional or systemic toxicity (which could have occurred
because of the fact that human sFasL can bind to murine
Fas). Not surprisingly, tumor burden at the onset of sFasL
administration determined the overall effectiveness of
sFasL therapy; animals with macroscopic tumor implants
had a less spectacular response compared with that seen in
animals with microscopic disease. These results underscore
the clinical potential for locoregional delivery of sFasL as
adjuvant therapy after pleurectomy or pleuropneumonec-
tomy in patients with mesotheliomas.
Data presented in this article clearly indicate that
Fas/FasL interactions can cooperate with cytotoxic agents
and immune effector cells to deliver potent apoptotic sig-
nals to mesothelioma cells. Further evaluation of the mech-
anisms responsible for this phenomenon may enable the
development of novel treatment regimens designed to
enhance apoptosis in mesotheliomas through activation of
Fas and other related death-signal pathways.
We thank Sharyn Childs for her assistance in the preparation of
this article. We also thank Arnold Mixon and Shawn Farid for per-
forming flow cytometric studies.
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Discussion
Dr Ralph A. Schmid (Berne, Switzerland). Did you look at
liver function in the animal studies? When you give FasL system-
ically, animals die of liver failure.
Dr Stewart. Actually, those studies came from intraperitoneal
injection of Jo2 agonistic antibodies to Fas, and there was massive
hepatic necrosis in those previous studies. However, with our
intraperitoneal injections of Fas, we saw no changes in liver mor-
phology, as evidenced by hematoxylin and eosin staining.
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